You are here: Industry Insights > Q BioMed

News List

Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada americanpharmaceuticalreview
August 11, 2021
Q BioMed Inc., a commercial-stage biotech company, announced that it recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing services and solutions to ...
Q BioMed Inks Strontium89 Supply Pact contractpharma
March 03, 2021
Q BioMed Inc. has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injection, USP) to be included on the Federal Supply Schedule (FSS).
Q BioMed's Uttroside-B Receives Orphan Drug Designation for Liver Cancer americanpharmaceuticalreview
February 03, 2021
Q BioMed announced the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most ...
Q BioMed Initiates GMP Production of Novel COVID-19 Therapeutic contractpharma
August 31, 2020
COVID-19 clinical trial planned for Q1 2021 supported by Canadian Government.
Q BioMed, Mannin Announce GMP Production of COVID-19 Therapeutic for Clinical Trial americanpharmaceuticalreview
August 27, 2020
Q BioMed announced with its technology partner, Mannin Research, a GMP production contract has been initiated for MAN-19, a clinical grade therapeutic intended to treat complications caused by COVID-19.
Global distribution partnership established for Strontium89 europeanpharmaceuticalreview
July 14, 2020
Q Biomed entered into a Named Patient Programme distribution agreement for Strontium89, a non-opioid metastatic bone cancer pain drug.
Q BioMed, Mannin Research Accelerate COVID-19 Response Initiatives contractpharma
April 23, 2020
Leveraging Mannin’s Tie2 based small molecule platform to address vascular leakage, a life-threatening COVID-19 complication.
Q BioMed Enters $7.8M Financial Restructuring contractpharma
April 09, 2020
Provides capital to bring FDA approved non-opioid, Strontium89 Chloride USP Injection drug to market.
Q BioMed Appoints Head of Global Regulatory Affairs contractpharma
April 01, 2020
Geoff Fatzinger will lead the global regulatory approval strategy for the commercialization of FDA approved, non-opioid Strontium89.
Q BioMed, Chemveda Form Cancer Collaboration contractpharma
September 16, 2019
Sign agreement for synthesis and manufacturing of liver cancer chemotherapeutic.

Previous page 1 2 Next page